Peptides as epigenetic modulators: therapeutic implications
Open Access
- 12 July 2019
- journal article
- review article
- Published by Springer Nature in Clinical Epigenetics
- Vol. 11 (1) , 1-14
Abstract
Peptides originating from different sources (endogenous, food derived, environmental, and synthetic) are able to influence different aspects of epigenetic regulation. Endogenous short peptides, resulting from proteolytic cleavage of proteins or upon translation of non-annotated out of frame transcripts, can block DNA methylation and hereby regulate gene expression. Peptides entering the body by digestion of food-related proteins can modulate DNA methylation and/or histone acetylation while environmental peptides, synthesized by bacteria, fungi, and marine sponges, mainly inhibit histone deacetylation. In addition, synthetic peptides that reverse or inhibit different epigenetic modifications of both histones and the DNA can be developed as well. Next to these DNA and histone modifications, peptides can also influence the expression of non-coding RNAs such as lncRNAs and the maturation of miRNAs. Seen the advantages over small molecules, the development of peptide therapeutics is an interesting approach to treat diseases with a strong epigenetic basis like cancer and Alzheimer’s disease. To date, only a limited number of drugs with a proven epigenetic mechanism of action have been approved by the FDA of which two (romidepsin and nesiritide) are peptides. A large knowledge gap concerning epigenetic effects of peptides is present, and this class of molecules deserves more attention in the development as epigenetic modulators. In addition, none of the currently approved peptide drugs are under investigation for their potential effects on epigenetics, hampering drug repositioning of these peptides to other indications with an epigenetic etiology.Keywords
This publication has 172 references indexed in Scilit:
- Lysine-specific demethylase 1 is a therapeutic target for fetal hemoglobin inductionNature Medicine, 2013
- Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferationProceedings of the National Academy of Sciences, 2012
- Histone Deacetylase Inhibitors from Burkholderia thailandensisJournal of Natural Products, 2011
- Thailandepsins: Bacterial Products with Potent Histone Deacetylase Inhibitory Activities and Broad-Spectrum Antiproliferative ActivitiesJournal of Natural Products, 2011
- Non-coding RNAs as regulators of gene expression and epigeneticsCardiovascular Research, 2011
- Acyldepsipeptide HDAC Inhibitor Production Induced in Burkholderia thailandensisOrganic Letters, 2011
- Regulation of chromatin by histone modificationsCell Research, 2011
- Design, Synthesis, Biological Evaluation, and Structural Characterization of Potent Histone Deacetylase Inhibitors Based on Cyclic α/β-Tetrapeptide ArchitecturesJournal of the American Chemical Society, 2009
- MicroRNAs: Target Recognition and Regulatory FunctionsCell, 2009
- Drug repositioning: identifying and developing new uses for existing drugsNature Reviews Drug Discovery, 2004